Clinical Trials Browser

Phase 2 × Oligodendroglioma × Irinotecan × Clear all

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Phase 2 Completed

97 enrolled 35 charts

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

NCT00360828 2017-03-23

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

Phase 2 Terminated

10 enrolled 6 charts

Astrocytoma, Brain Neoplasms, Glioma, Neurologic Manifestations, Oligodendroglioma

NCT00352521 2014-07-22

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00268359 2014-07-21

Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00004078 2013-06-14

Irinotecan in Treating Children With Refractory Solid Tumors

Phase 2 Completed

Familial ependymoma, Astrocytoma, Medulloblastoma, Neuroblastoma, Oligodendroglioma, Osteosarcoma, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Optic Nerve Glioma

NCT00004068 2011-10-04

Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor

Phase 2 Completed

Astrocytoma, Oligodendroglioma, Central Nervous System Neoplasms